Efficacy of CAR-T-Cell-Based Immunotherapies in Patients With Glioma: A Systematic Review and Meta-Analysis.
CAR-T cell therapy shows early promise against aggressive brain tumors, though response rates remain modest and warrant continued investigation.
Glioma is an aggressive intracranial malignancy associated with a poor prognosis and high mortality. Efficacy analysis of 12 studies (n = 153 evaluable patients) demonstrated a pooled overall response rate of 16.9% (95% confidence interval [CI], 8.0%-32.2%), driven by complete responses in 8.1% (95% CI, 3.5%-17.8%) and ...
What the study was
- Study design
- Meta-analysis
- Population
- patients
- Sample size
- 153
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of cellular and molecular medicine
Why it surfaced
Score 7/10 [NOVEL_TREATMENT]: Meta-analysis (Journal Article) matched 'Novel therapeutics immunotherapy CAR-T'. Components — novelty:1/3, relevance:2/3, design:2/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.